BioTelemetry (BEAT) Upgraded to “Sell” by BidaskClub

BioTelemetry (NASDAQ:BEAT) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Tuesday, December 19th.

A number of other analysts have also recently commented on the stock. Off Wall Street started coverage on shares of BioTelemetry in a report on Friday, September 15th. They set a “sell” rating for the company. Zacks Investment Research lowered shares of BioTelemetry from a “hold” rating to a “strong sell” rating in a research report on Thursday, November 2nd. SunTrust Banks started coverage on shares of BioTelemetry in a research report on Monday, October 23rd. They issued a “buy” rating and a $41.00 price target for the company. Dougherty & Co reiterated a “buy” rating and issued a $40.00 price target on shares of BioTelemetry in a research report on Wednesday, November 8th. Finally, Raymond James Financial started coverage on shares of BioTelemetry in a research report on Thursday, October 26th. They issued an “outperform” rating and a $37.00 price target for the company. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. BioTelemetry currently has an average rating of “Hold” and an average price target of $42.86.

BioTelemetry (NASDAQ:BEAT) traded up $1.10 on Tuesday, hitting $31.60. 476,800 shares of the stock traded hands, compared to its average volume of 566,576. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.60 and a quick ratio of 1.48. BioTelemetry has a 1 year low of $21.05 and a 1 year high of $39.20. The stock has a market capitalization of $988.45, a PE ratio of 24.12, a price-to-earnings-growth ratio of 1.40 and a beta of 0.53.

BioTelemetry (NASDAQ:BEAT) last announced its earnings results on Tuesday, November 7th. The medical research company reported $0.16 EPS for the quarter, missing the Zacks’ consensus estimate of $0.25 by ($0.09). BioTelemetry had a net margin of 16.10% and a return on equity of 13.66%. The business had revenue of $81.02 million for the quarter, compared to analysts’ expectations of $82.10 million. During the same period in the prior year, the company posted $0.21 earnings per share. The firm’s quarterly revenue was up 52.7% on a year-over-year basis. equities analysts predict that BioTelemetry will post 0.83 earnings per share for the current year.

Several large investors have recently modified their holdings of BEAT. Teachers Advisors LLC boosted its position in shares of BioTelemetry by 7.6% during the first quarter. Teachers Advisors LLC now owns 46,786 shares of the medical research company’s stock worth $1,354,000 after acquiring an additional 3,297 shares during the last quarter. US Bancorp DE bought a new position in shares of BioTelemetry during the second quarter worth $145,000. Municipal Employees Retirement System of Michigan boosted its position in shares of BioTelemetry by 5.8% during the second quarter. Municipal Employees Retirement System of Michigan now owns 6,700 shares of the medical research company’s stock worth $224,000 after acquiring an additional 370 shares during the last quarter. Great West Life Assurance Co. Can boosted its position in shares of BioTelemetry by 4.1% during the second quarter. Great West Life Assurance Co. Can now owns 40,699 shares of the medical research company’s stock worth $1,361,000 after acquiring an additional 1,600 shares during the last quarter. Finally, Texas Permanent School Fund boosted its position in shares of BioTelemetry by 1.8% during the second quarter. Texas Permanent School Fund now owns 20,921 shares of the medical research company’s stock worth $700,000 after acquiring an additional 380 shares during the last quarter. Hedge funds and other institutional investors own 82.34% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://stocknewstimes.com/2018/01/11/biotelemetry-beat-upgraded-to-sell-by-bidaskclub.html.

BioTelemetry Company Profile

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Analyst Recommendations for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply